Japan To Reimburse Zolgensma – But At Lower Price Than US
NHI Scheme Grants Coverage
Executive Summary
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.
You may also be interested in...
Inventiva Gets OK To Resume Phase III MASH Study
Inventiva can resume screening and randomizing for its Phase III trial of lanifibranor in MASH, about three weeks after pausing the study due to a suspected unexpected serious adverse event.
One Way To Get Ahead: Biogen To Test Spinraza Given After Novartis’s Zolgensma
Biogen said some spinal muscular atrophy patients are currently being treated with Spinraza after receiving the Novartis gene therapy – its main competitor – so it will start a study of the risk/benefit in 2021.
Japan Nods Include Global Firsts For Duvroq, Vafseo And First Local Biosimilar Humira
Japan’s regulators have approved a large batch of new products, including a novel antibody from Chugai, two world-first nods for the country’s second HIF-PH inhibitors and an asthma therapy, and the first Humira biosimilar in Japan – as well as five drugs from Novartis.